Spero Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Welcome, everyone. We have Spero Therapeutics here presenting at the 33rd Annual Healthcare Conference at Oppenheimer. I'm Joel Sendek, Head of Healthcare Life Sciences Research here, and we are really excited to have Sath Shukla from Spero. He's the Chief Financial Officer, and I will I'll turn it over to Sath.
Great, and thanks, Joel. (inaudible) Thanks for having this conference. A quick knowledge, these are notes that statements are forward looking. And after that, let's dive into the story.
Spero is approaching our 10th anniversary. And at this stage, we believe ourselves to be a leader in infectious and rare diseases. The company has three late-stage medicines, targeting areas with high unmet need and strong commercial prospects. And I'm very fortunate to work with a great team, including my colleagues in the executive team who have developed significant clinical, regulatory and operational experience that has contributed to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |